J Rheum Dis.  2011 Dec;18(4):231-233. 10.4078/jrd.2011.18.4.231.

Persistence with Anti-TNF Therapies in Patients with Rheumatoid Arthritis

• Cha HS

• KMID: 2223125
• DOI: http://doi.org/10.4078/jrd.2011.18.4.231

Abstract

No abstract available.

MeSH Terms

Arthritis, Rheumatoid
Humans

Reference

References

1. Nixon R, Bansback N, Brennan A. The efficacy of in-hibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford). 2007; 46:1140–7.

2. Venkateshan SP, Sidhu S, Malhotra S, Pandhi P. Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis. Pharmacology. 2009; 83:1–9.

3. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis. 2007; 66:1473–8.

4. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006; 54:3399–407.

5. Carmona L, Gómez-Reino JJ. BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006; 8:R72.

6. Heiberg MS, Koldingsnes W, Mikkelsen K, R⊘devand E, Kaufmann C, Mowinckel P, et al. The comparative one-year performance of antitumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008; 59:234–40.

7. Duclos M, Gossec L, Ruyssen-Witrand A, Salliot C, Luc M, Guignard S, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol. 2006; 33:2433–8.

8. Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, et al. Longterm effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford). 2011; 50:196–203.

9. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL. British Society for Rheumatology Biologics Register. Impact of concomitant use of DM-ARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011; 70:583–9.

10. Busquets N, Tomero E, Descalzo MÁ, Ponce A, Ortiz-Santamaría V, Surís X, et al. BIOBADASER 2.0 Study Group. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology (Oxford). 2011; 50:1999–2004.

11. Cho SK, Sung YK, Choi CB, Uhm WS, Kim TH, Jun JB, et al. Treatment persistence with TNF Blocker in Korean Rheumatoid Arthritis Patients. J Rheum Dis. 2011; 18:161–7.

12. Gómez-Reino JJ, Rodríguez-Lozano C, Campos-Fernán-dez C, Montoro M, Descalzo MA, Carmona L. on behalf of the BIOBADASER 2.0 Study Group. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis In press. 2011.

13. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during longterm followup. JAMA. 2011; 305:1460–8.